These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 31696302)
1. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302 [TBL] [Abstract][Full Text] [Related]
2. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618 [TBL] [Abstract][Full Text] [Related]
3. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
5. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J; Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714 [TBL] [Abstract][Full Text] [Related]
6. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
9. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482 [TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836 [TBL] [Abstract][Full Text] [Related]
11. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733 [TBL] [Abstract][Full Text] [Related]
12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms]. Li Y; Zhang FS; Guo L; Ying JM Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169 [No Abstract] [Full Text] [Related]
13. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917 [TBL] [Abstract][Full Text] [Related]
14. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752 [TBL] [Abstract][Full Text] [Related]
16. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576 [TBL] [Abstract][Full Text] [Related]
17. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126 [TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111 [TBL] [Abstract][Full Text] [Related]